Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Biden leaning on Defense Production Act to bolster COVID-19 vaccine supplies

By Brian Buntz | January 21, 2021

Biden

[Joe Biden photo from Wikipedia]

President Joe Biden has unveiled a series of anti-COVID-19 measures in his first full day in office, including signing an executive order instructing federal agencies to use the Defense Production Act (DPA) and other tools to speed the manufacture of COVID-19 vaccines and materials.

In total, the president has signed 10 executive orders intended to curb the spread of the novel coronavirus.

According to the “National Strategy for the COVID-19 Response and Pandemic Preparedness” document, the Biden administration will use the Defense Production Act to “fill any distribution gaps, including with respect to any needed refrigeration, transportation, or storage facilities.”

Biden has also moved to create a centralized federal approach to virus testing while ramping up the U.S. government’s involvement in vaccine distribution.

“President Biden is using tools that have been sitting in the toolbox since the pandemic started and, indeed, since the 1950s — but were not leveraged in earnest under the previous Administration,” said Alex Hontos, a partner at the law firm Dorsey & Whitney.

The DPA will give Biden “broad authority to order goods and services,” Hontos said. It will also enable the administration to prioritize the production of goods such as vaccines, respirators and personal protective equipment. The law also will allow the administration to make loan guarantees and offer other incentives to boost industrial capacity.

One of the Defense Production Act’s core advantages is the speed it offers the president. The fact that it does not require Biden to get Congressional support is notable, given that Congress is in transition, contemplating impeachment and holding hearings on new nominees. The DPA is “a good way for the Administration to organize the pandemic response without getting bogged down on the Hill,” Hontos said. “I expect the Biden Administration to use the DPA extensively.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moscow
Moscow ramping up COVID-19 vaccination
Johnson & Johnson
FDA authorizes J&J’s single-dose COVID-19 vaccine
President Joe Biden
Biden to order analysis of pharma supply chain
COVID-19 vaccine
5 takeaways from the latest White House COVID-19 response team briefing

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards